麻豆原创

Drug Pipeline

Drug Pipeline 麻豆原创 Research Reports

Drug Pipeline 麻豆原创 Research Reports Analysis and Trends

Discovering and bringing new drugs to mainstream commercial market typically takes an average of 10-15 years of research and clinical development efforts. Drug developers need to make sure safe and effective drug available for patient in quick time. The first step is to target the protein available in the patient鈥檚 body that is associated with microorganism causing a disease, through tracking of cellular network of proteins an appropriate target for a drug is selected. Through a series of trials, right drug candidate got chosen.
According to 鈥淣OVARTIS鈥, bringing a new drug in market takes 14 years of research and cost around USD 2 billion, 10K+ clinical trials out of these, one leads to successful drug development.
Title Published Pages Price
Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Dec 28 2022 60 USD 2,000.00
Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Dec 28 2022 49 USD 3,500.00
Recurrent Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Dec 28 2022 45 USD 2,000.00
Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Dec 28 2022 200 USD 2,000.00
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Dec 28 2022 2271 USD 2,500.00
Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 734 USD 2,500.00
Heart Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 35 USD 2,000.00
Keloids Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 43 USD 2,000.00
Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 155 USD 2,000.00
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 79 USD 2,000.00
Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 85 USD 2,000.00
Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 1699 USD 2,500.00
Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 99 USD 2,000.00
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 299 USD 2,500.00
Neurofibromatoses Type I (Von Recklinghausen鈥檚 Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 72 USD 2,000.00
Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 50 USD 3,500.00
Canavan Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 37 USD 2,000.00
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 77 USD 2,000.00
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 159 USD 3,500.00
Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 40 USD 2,000.00
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 73 USD 2,000.00
Myocardial Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 53 USD 2,000.00
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 53 USD 3,500.00
Ornithine-Transcarbamylase Deficiency Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 61 USD 2,000.00
Radiodermatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 54 USD 2,000.00
RAF Proto Oncogene Serine, Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 117 USD 3,500.00
Short Bowel Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 63 USD 2,000.00
Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 79 USD 2,000.00
Pertussis (Whooping Cough) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 106 USD 2,000.00
Wounds Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 246 USD 2,000.00
Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 504 USD 2,500.00
Sicca Syndrome (Sjogren) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 120 USD 2,000.00
Bullous Pemphigoid Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 55 USD 2,000.00
Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 574 USD 2,500.00
Graves Diseases Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 36 USD 2,000.00
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 99 USD 2,000.00
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 1663 USD 2,500.00
Wilson Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 62 USD 2,000.00
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 43 USD 3,500.00
Globoid Cell Leukodystrophy (Krabbe Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 47 USD 2,000.00
Usher Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 59 USD 2,000.00
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 67 USD 3,500.00
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 696 USD 2,500.00
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 68 USD 2,000.00
Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 71 USD 2,000.00
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 71 USD 3,500.00
Gaucher Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 108 USD 2,000.00
Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 589 USD 2,500.00
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 125 USD 3,500.00
Peptic Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 76 USD 2,000.00

Clients Who Trust Us

麻豆原创 Research Reports Inc. Customers

Need tailor made market research solution? We can help you with that too.

About Us

At 麻豆原创 we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer鈥檚 needs, be it custom research or syndicated research reports.

Contact Us

麻豆原创 Research Reports, Inc
16192 Coastal Hwy
Lewes
, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

User login

Stay Connected